Relmada Therapeutics has appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer for Urology & Uro-Oncology. Dr. Jakobsen, who previously spent nine years at Ferring Pharmaceuticals leading the ADSTILADRIN program, will oversee clinical development for the company's pipeline, including the upcoming Phase 3 SPECTRUM registrational program for NDV-01.
Relmada announced the hiring of Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology, citing his nine-year tenure at Ferring where he led the pivotal ADSTILADRIN program to FDA, EMA, PMDA and Health Canada approvals. This strengthens leadership ahead of the planned Phase 3 SPECTRUM program for NDV-01, but it is a personnel appointment without quantified financial or trial results, so it does not materially change the company's outlook by itself.
- • Appointment of a new Chief Development Officer announced November 16, 2026
- • Preparation to initiate the Phase 3 SPECTRUM registrational program for NDV-01
- • Relmada remains a clinical-stage company dependent on the success of NDV-01 and sepranolone trials
- • The article notes potential delays or failure to initiate the planned Phase 3 SPECTRUM program